---
title: "Can-Fite BioPharma Tumbles 11% in After-Hours Trading to Fresh Low"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291010102.md"
description: "Can-Fite (CANF) dropped 11% after-hours to $2.45, a record low, despite Japan patent nod for obesity drug Namodenoson."
datetime: "2026-06-26T21:21:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291010102.md)
  - [en](https://longbridge.com/en/news/291010102.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291010102.md)
generator: "portal-rs"
---

# Can-Fite BioPharma Tumbles 11% in After-Hours Trading to Fresh Low

Can-Fite BioPharma(CANF.US) 盘后时段股价跌至**2.45 美元**，跌幅**10.91%**，触及历史新低。

消息面上，公司于 6 月 26 日获日本专利局批准 Namodenoson 抗肥胖技术专利，该专利覆盖 A3 腺苷受体激动剂用于减脂和治疗肥胖症，扩展了公司全球知识产权组合。尽管获得专利利好，股价仍延续跌势创出新低。

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance](https://longbridge.com/en/news/295654944.md)
- [Can-Fite submits Phase 2 Lowe syndrome trial protocol for Piclidenoson to Italy hospital](https://longbridge.com/en/news/294682694.md)
- [Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting](https://longbridge.com/en/news/278625962.md)
- [Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients](https://longbridge.com/en/news/291432421.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**